Bidding war for Guidant begins
This article was originally published in Clinica
Executive Summary
Pursuing Guidant in full vigour, Boston Scientific has today offered to buy the cardiology company for $73 per share instead of $72 as previously proposed, upping the value of the transaction to approximately $25.3bn. Boston's move comes just 24 hours after Johnson & Johnson threw in an additional $1.7bn to its proposed price for Guidant.